Conclusion of Single Sales Contract or Supply Contract
1. Type of sales or supply contract Other sales or supply contracts
- Name of contract concluded COVID-19 Vaccine CMO Contract (Statement of work of 'Collaboration and License Agreement')
2. Details of contract Contract amount (KRW) 91,484,160,000
Sales of the latest fiscal year (KRW) 225,610,784,857
Ratio to sales (%) 40.55
Classified as a large-sized corporation? No
3. Counterparty to contract Novavax, Inc.
- Relationship to company -
4. Regions of sales or supply (markets served) -
5. Contract period Start date 2021-12-23
End date 2022-12-31
6. Terms and conditions of contract Production and supply of Novavax's COVID-19 Vaccine(DS)
7. Effective date of contract (receipt of orders) 2021-12-23
8. Withholding of disclosure Reasons for withholding disclosure -
Withholding period -
9. Other matters to be factored into investment decisions
- The above contract amount is the amount obtained by converting USD 76,800,000 based on the basic rate of exchange first published (1,191.20 KRW/USD) at the time of reporting(December 23rd, 2021).

- The above sales amount is the company's sales based on the last year's individual financial statements.

- The above contract amount is based on the client's minimum committed amount and may increase depending on actual purchase amount.

- Novavax shall produce COVID-19 vaccine product with the drug substance produced by SK bioscience. SK bioscience shall receive fee incentive on net sales of the product apart from the above contract amount.

- SK bioscience has secured rights to sell some part of the vaccine product produced under the license agreement in Korea, Thailand and Vietnam upon requests and shall pay fee incentive on net sales of the product to Novavax.

- The above contract period may differ depending on revisions of the contract terms by consensus.
※ Related disclosure -

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

SK Bioscience Co. Ltd. published this content on 24 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 December 2021 07:36:06 UTC.